Literature DB >> 26126123

DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites.

Ragul Gowthaman1, Sven A Miller1, Steven Rogers1, Jittasak Khowsathit1, Lan Lan1, Nan Bai1, David K Johnson1, Chunjing Liu1, Liang Xu1, Asokan Anbanandam1, Jeffrey Aubé1, Anuradha Roy1, John Karanicolas1.   

Abstract

Protein-protein interactions represent an exciting and challenging target class for therapeutic intervention using small molecules. Protein interaction sites are often devoid of the deep surface pockets presented by "traditional" drug targets, and crystal structures reveal that inhibitors typically engage these sites using very shallow binding modes. As a consequence, modern virtual screening tools developed to identify inhibitors of traditional drug targets do not perform as well when they are instead deployed at protein interaction sites. To address the need for novel inhibitors of important protein interactions, here we introduce an alternate docking strategy specifically designed for this regime. Our method, termed DARC (Docking Approach using Ray-Casting), matches the topography of a surface pocket "observed" from within the protein to the topography "observed" when viewing a potential ligand from the same vantage point. We applied DARC to carry out a virtual screen against the protein interaction site of human antiapoptotic protein Mcl-1 and found that four of the top-scoring 21 compounds showed clear inhibition in a biochemical assay. The Ki values for these compounds ranged from 1.2 to 21 μM, and each had ligand efficiency comparable to promising small-molecule inhibitors of other protein-protein interactions. These hit compounds do not resemble the natural (protein) binding partner of Mcl-1, nor do they resemble any known inhibitors of Mcl-1. Our results thus demonstrate the utility of DARC for identifying novel inhibitors of protein-protein interactions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26126123      PMCID: PMC4707132          DOI: 10.1021/acs.jmedchem.5b00150

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  115 in total

1.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

2.  Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database.

Authors:  Alícia P Higueruelo; Adrian Schreyer; G Richard J Bickerton; Will R Pitt; Colin R Groom; Tom L Blundell
Journal:  Chem Biol Drug Des       Date:  2009-11       Impact factor: 2.817

Review 3.  Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.

Authors:  Eric B Fauman; Brajesh K Rai; Enoch S Huang
Journal:  Curr Opin Chem Biol       Date:  2011-06-23       Impact factor: 8.822

4.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

5.  Conformer generation with OMEGA: learning from the data set and the analysis of failures.

Authors:  Paul C D Hawkins; Anthony Nicholls
Journal:  J Chem Inf Model       Date:  2012-11-12       Impact factor: 4.956

6.  Synthesis of cell-permeable stapled BH3 peptide-based Mcl-1 inhibitors containing simple aryl and vinylaryl cross-linkers.

Authors:  Avinash Muppidi; Kenichiro Doi; Carlo P Ramil; Hong-Gang Wang; Qing Lin
Journal:  Tetrahedron       Date:  2014-10-21       Impact factor: 2.457

7.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

8.  Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.

Authors:  Baptiste Villemagne; Marion Flipo; Nicolas Blondiaux; Céline Crauste; Sandra Malaquin; Florence Leroux; Catherine Piveteau; Vincent Villeret; Priscille Brodin; Bruno O Villoutreix; Olivier Sperandio; Sameh H Soror; Alexandre Wohlkönig; René Wintjens; Benoit Deprez; Alain R Baulard; Nicolas Willand
Journal:  J Med Chem       Date:  2014-05-28       Impact factor: 7.446

9.  Selectivity by small-molecule inhibitors of protein interactions can be driven by protein surface fluctuations.

Authors:  David K Johnson; John Karanicolas
Journal:  PLoS Comput Biol       Date:  2015-02-23       Impact factor: 4.475

10.  Fast docking on graphics processing units via Ray-Casting.

Authors:  Karen R Khar; Lukasz Goldschmidt; John Karanicolas
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more
  11 in total

Review 1.  In silico structure-based approaches to discover protein-protein interaction-targeting drugs.

Authors:  Woong-Hee Shin; Charles W Christoffer; Daisuke Kihara
Journal:  Methods       Date:  2017-08-09       Impact factor: 3.608

2.  Ultra-High-Throughput Structure-Based Virtual Screening for Small-Molecule Inhibitors of Protein-Protein Interactions.

Authors:  David K Johnson; John Karanicolas
Journal:  J Chem Inf Model       Date:  2016-01-14       Impact factor: 4.956

3.  The Ser/Thr Protein Kinase Protein-Protein Interaction Map of M. tuberculosis.

Authors:  Fan-Lin Wu; Yin Liu; He-Wei Jiang; Yi-Zhao Luan; Hai-Nan Zhang; Xiang He; Zhao-Wei Xu; Jing-Li Hou; Li-Yun Ji; Zhi Xie; Daniel M Czajkowsky; Wei Yan; Jiao-Yu Deng; Li-Jun Bi; Xian-En Zhang; Sheng-Ce Tao
Journal:  Mol Cell Proteomics       Date:  2017-06-01       Impact factor: 5.911

Review 4.  Computational Tools and Strategies to Develop Peptide-Based Inhibitors of Protein-Protein Interactions.

Authors:  Maxence Delaunay; Tâp Ha-Duong
Journal:  Methods Mol Biol       Date:  2022

5.  DARC 2.0: Improved Docking and Virtual Screening at Protein Interaction Sites.

Authors:  Ragul Gowthaman; Sergey Lyskov; John Karanicolas
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

6.  Introduction to the Rosetta Special Collection.

Authors:  Sagar D Khare; Timothy A Whitehead
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

Review 7.  Protocols for Molecular Modeling with Rosetta3 and RosettaScripts.

Authors:  Brian J Bender; Alberto Cisneros; Amanda M Duran; Jessica A Finn; Darwin Fu; Alyssa D Lokits; Benjamin K Mueller; Amandeep K Sangha; Marion F Sauer; Alexander M Sevy; Gregory Sliwoski; Jonathan H Sheehan; Frank DiMaio; Jens Meiler; Rocco Moretti
Journal:  Biochemistry       Date:  2016-08-16       Impact factor: 3.162

8.  DeepConv-DTI: Prediction of drug-target interactions via deep learning with convolution on protein sequences.

Authors:  Ingoo Lee; Jongsoo Keum; Hojung Nam
Journal:  PLoS Comput Biol       Date:  2019-06-14       Impact factor: 4.475

Review 9.  Macromolecular modeling and design in Rosetta: recent methods and frameworks.

Authors:  Julia Koehler Leman; Brian D Weitzner; Steven M Lewis; Jared Adolf-Bryfogle; Nawsad Alam; Rebecca F Alford; Melanie Aprahamian; David Baker; Kyle A Barlow; Patrick Barth; Benjamin Basanta; Brian J Bender; Kristin Blacklock; Jaume Bonet; Scott E Boyken; Phil Bradley; Chris Bystroff; Patrick Conway; Seth Cooper; Bruno E Correia; Brian Coventry; Rhiju Das; René M De Jong; Frank DiMaio; Lorna Dsilva; Roland Dunbrack; Alexander S Ford; Brandon Frenz; Darwin Y Fu; Caleb Geniesse; Lukasz Goldschmidt; Ragul Gowthaman; Jeffrey J Gray; Dominik Gront; Sharon Guffy; Scott Horowitz; Po-Ssu Huang; Thomas Huber; Tim M Jacobs; Jeliazko R Jeliazkov; David K Johnson; Kalli Kappel; John Karanicolas; Hamed Khakzad; Karen R Khar; Sagar D Khare; Firas Khatib; Alisa Khramushin; Indigo C King; Robert Kleffner; Brian Koepnick; Tanja Kortemme; Georg Kuenze; Brian Kuhlman; Daisuke Kuroda; Jason W Labonte; Jason K Lai; Gideon Lapidoth; Andrew Leaver-Fay; Steffen Lindert; Thomas Linsky; Nir London; Joseph H Lubin; Sergey Lyskov; Jack Maguire; Lars Malmström; Enrique Marcos; Orly Marcu; Nicholas A Marze; Jens Meiler; Rocco Moretti; Vikram Khipple Mulligan; Santrupti Nerli; Christoffer Norn; Shane Ó'Conchúir; Noah Ollikainen; Sergey Ovchinnikov; Michael S Pacella; Xingjie Pan; Hahnbeom Park; Ryan E Pavlovicz; Manasi Pethe; Brian G Pierce; Kala Bharath Pilla; Barak Raveh; P Douglas Renfrew; Shourya S Roy Burman; Aliza Rubenstein; Marion F Sauer; Andreas Scheck; William Schief; Ora Schueler-Furman; Yuval Sedan; Alexander M Sevy; Nikolaos G Sgourakis; Lei Shi; Justin B Siegel; Daniel-Adriano Silva; Shannon Smith; Yifan Song; Amelie Stein; Maria Szegedy; Frank D Teets; Summer B Thyme; Ray Yu-Ruei Wang; Andrew Watkins; Lior Zimmerman; Richard Bonneau
Journal:  Nat Methods       Date:  2020-06-01       Impact factor: 28.547

10.  Discovery of novel isoliquiritigenin analogue ISL-17 as a potential anti-gastric cancer agent.

Authors:  Fengchang Huang; Jin Wang; Yi Xu; Yunfei Zhang; Ning Xu; Liang Yin
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.